tiprankstipranks
Halozyme Therapeutics (HALO)
NASDAQ:HALO
US Market
HALO
Halozyme
RESEARCH TOOLSreports
Want to see HALO full AI Analyst Report?

Halozyme (HALO) Stock Forecast & Price Target

1,216 Followers
See the Price Targets and Ratings of:

HALO Analyst Ratings

Moderate Buy
8Ratings
Moderate Buy
5 Buy
2 Hold
1 Sell
Based on 8 analysts giving stock ratings to
Halozyme
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

HALO Stock 12 Month Forecast

Average Price Target

$93.75
▲(14.43% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Halozyme in the last 3 months. The average price target is $93.75 with a high forecast of $115.00 and a low forecast of $57.00. The average price target represents a 14.43% change from the last price of $81.93.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"56":"$56","71":"$71","86":"$86","101":"$101","116":"$116"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":115,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$115.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":93.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$93.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$57.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[56,71,86,101,116],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,82.54,85.03692307692309,87.53384615384616,90.03076923076924,92.52769230769232,95.02461538461539,97.52153846153847,100.01846153846154,102.51538461538462,105.0123076923077,107.50923076923077,110.00615384615385,112.50307692307692,{"y":115,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,82.54,83.4023076923077,84.2646153846154,85.12692307692308,85.98923076923077,86.85153846153847,87.71384615384616,88.57615384615384,89.43846153846154,90.30076923076923,91.16307692307693,92.02538461538461,92.8876923076923,{"y":93.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,82.54,80.57538461538462,78.61076923076924,76.64615384615385,74.68153846153847,72.71692307692308,70.7523076923077,68.78769230769231,66.82307692307693,64.85846153846154,62.893846153846155,60.92923076923077,58.964615384615385,{"y":57,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":59.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.34,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.94,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.19,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.1,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.3,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.45,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.85,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.4,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.96,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.14,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.01,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.54,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$115.00Average Price Target$93.75Lowest Price Target$57.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on HALO
David Risinger
Leerink Partners
Leerink Partners
$83→$110
Buy
34.26%
Upside
Upgraded
08/07/26
Halozyme upgraded to Outperform from Market Perform at LeerinkHalozyme upgraded to Outperform from Market Perform at Leerink
Citizens JMP Analyst forecast on HALO
Jason Butler
Citizens JMP
Citizens JMP
$92→$93
Buy
13.51%
Upside
Reiterated
08/07/26
Halozyme price target raised to $93 from $92 at CitizensHalozyme price target raised to $93 from $92 at Citizens
Morgan Stanley Analyst forecast on HALO
Sean Laaman
Morgan Stanley
Morgan Stanley
$93→$105
Buy
28.16%
Upside
Assigned
08/07/26
Morgan Stanley Remains a Buy on Halozyme (HALO)
TD Cowen Analyst forecast on HALO
Brendan Smith
TD Cowen
TD Cowen
$96→$105
Buy
28.16%
Upside
Assigned
08/07/26
Analysts Offer Insights on Healthcare Companies: Compass Therapeutics (NASDAQ: CMPX) and Halozyme (NASDAQ: HALO)
Wells Fargo Analyst forecast on HALO
Mohit Bansal
Wells Fargo
Wells Fargo
$75→$95
Hold
15.95%
Upside
Assigned
08/07/26
Analysts Offer Insights on Healthcare Companies: Korro Bio (NASDAQ: KRRO), Halozyme (NASDAQ: HALO) and Resmed (NYSE: RMD)
H.C. Wainwright Analyst forecast on HALO
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$95→$115
Buy
40.36%
Upside
Reiterated
08/07/26
Halozyme price target raised to $115 from $95 at H.C. WainwrightHalozyme price target raised to $115 from $95 at H.C. Wainwright
Goldman Sachs Analyst forecast on HALO
Corinne Johnson
Goldman Sachs
Goldman Sachs
$57
Sell
-30.43%
Downside
Reiterated
06/14/26
Analysts Offer Insights on Healthcare Companies: Halozyme (NASDAQ: HALO), SAB Biotherapeutics (NASDAQ: SABS) and Design Therapeutics (NASDAQ: DSGN)
J.P. Morgan Analyst forecast on HALO
Unknown Analyst
J.P. Morgan
Not Ranked
J.P. Morgan
$70
Hold
-14.56%
Downside
Reiterated
05/20/26
J.P. Morgan Sticks to Its Hold Rating for Halozyme (HALO)
Benchmark Co. Analyst forecast on HALO
Robert Wasserman
Benchmark Co.
Benchmark Co.
$75→$90
Buy
9.85%
Upside
Reiterated
02/19/26
Halozyme price target raised to $90 from $75 at BenchmarkHalozyme price target raised to $90 from $75 at Benchmark
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on HALO
David Risinger
Leerink Partners
Leerink Partners
$83→$110
Buy
34.26%
Upside
Upgraded
08/07/26
Halozyme upgraded to Outperform from Market Perform at LeerinkHalozyme upgraded to Outperform from Market Perform at Leerink
Citizens JMP Analyst forecast on HALO
Jason Butler
Citizens JMP
Citizens JMP
$92→$93
Buy
13.51%
Upside
Reiterated
08/07/26
Halozyme price target raised to $93 from $92 at CitizensHalozyme price target raised to $93 from $92 at Citizens
Morgan Stanley Analyst forecast on HALO
Sean Laaman
Morgan Stanley
Morgan Stanley
$93→$105
Buy
28.16%
Upside
Assigned
08/07/26
Morgan Stanley Remains a Buy on Halozyme (HALO)
TD Cowen Analyst forecast on HALO
Brendan Smith
TD Cowen
TD Cowen
$96→$105
Buy
28.16%
Upside
Assigned
08/07/26
Analysts Offer Insights on Healthcare Companies: Compass Therapeutics (NASDAQ: CMPX) and Halozyme (NASDAQ: HALO)
Wells Fargo Analyst forecast on HALO
Mohit Bansal
Wells Fargo
Wells Fargo
$75→$95
Hold
15.95%
Upside
Assigned
08/07/26
Analysts Offer Insights on Healthcare Companies: Korro Bio (NASDAQ: KRRO), Halozyme (NASDAQ: HALO) and Resmed (NYSE: RMD)
H.C. Wainwright Analyst forecast on HALO
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
$95→$115
Buy
40.36%
Upside
Reiterated
08/07/26
Halozyme price target raised to $115 from $95 at H.C. WainwrightHalozyme price target raised to $115 from $95 at H.C. Wainwright
Goldman Sachs Analyst forecast on HALO
Corinne Johnson
Goldman Sachs
Goldman Sachs
$57
Sell
-30.43%
Downside
Reiterated
06/14/26
Analysts Offer Insights on Healthcare Companies: Halozyme (NASDAQ: HALO), SAB Biotherapeutics (NASDAQ: SABS) and Design Therapeutics (NASDAQ: DSGN)
J.P. Morgan Analyst forecast on HALO
Unknown Analyst
J.P. Morgan
Not Ranked
J.P. Morgan
$70
Hold
-14.56%
Downside
Reiterated
05/20/26
J.P. Morgan Sticks to Its Hold Rating for Halozyme (HALO)
Benchmark Co. Analyst forecast on HALO
Robert Wasserman
Benchmark Co.
Benchmark Co.
$75→$90
Buy
9.85%
Upside
Reiterated
02/19/26
Halozyme price target raised to $90 from $75 at BenchmarkHalozyme price target raised to $90 from $75 at Benchmark
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
ACRVAcrivon Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
TNYATenaya Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Halozyme

3 Months
Brendan SmithTD Cowen
Success Rate
13/19 ratings generated profit
68%
Average Return
+8.97%
Copying Brendan Smith's trades and holding each position for 3 Months would result in 68.42% of your transactions generating a profit, with an average return of +8.97% per trade.
1 Year
Brendan SmithTD Cowen
Success Rate
18/19 ratings generated profit
95%
Average Return
+33.13%
Copying Brendan Smith's trades and holding each position for 1 Year would result in 94.74% of your transactions generating a profit, with an average return of +33.13% per trade.
2 Years
Mitchell KapoorH.C. Wainwright
Success Rate
33/34 ratings generated profit
97%
Average Return
+62.22%
Copying Mitchell Kapoor's trades and holding each position for 2 Years would result in 97.06% of your transactions generating a profit, with an average return of +62.22% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HALO Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
1
1
1
0
0
Buy
8
8
10
7
8
Hold
1
2
3
3
2
Sell
0
0
1
1
1
Strong Sell
0
0
0
0
0
total
10
11
15
11
11
In the current month, HALO has received 8 Buy Ratings, 2 Hold Ratings, and 1 Sell Ratings. HALO average Analyst price target in the past 3 months is 93.75.
Each month's total comprises the sum of three months' worth of ratings.

HALO Financial Forecast

HALO Earnings Forecast

Next quarter’s earnings estimate for HALO is $2.24 with a range of $1.95 to $2.37. The previous quarter’s EPS was $2.28. HALO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year HALO has Performed in-line its overall industry.
Next quarter’s earnings estimate for HALO is $2.24 with a range of $1.95 to $2.37. The previous quarter’s EPS was $2.28. HALO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year HALO has Performed in-line its overall industry.

HALO Sales Forecast

Next quarter’s sales forecast for HALO is $482.27M with a range of $458.00M to $495.00M. The previous quarter’s sales results were $481.00M. HALO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year HALO has Performed in-line its overall industry.
Next quarter’s sales forecast for HALO is $482.27M with a range of $458.00M to $495.00M. The previous quarter’s sales results were $481.00M. HALO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year HALO has Performed in-line its overall industry.

HALO Stock Forecast FAQ

What is HALO’s average 12-month price target, according to analysts?
Based on analyst ratings, Halozyme Therapeutics’s 12-month average price target is 93.75.
    What is HALO’s upside potential, based on the analysts’ average price target?
    Halozyme Therapeutics has 14.43% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is HALO a Buy, Sell or Hold?
          Halozyme Therapeutics has a consensus rating of Moderate Buy which is based on 5 buy ratings, 2 hold ratings and 1 sell ratings.
            What is Halozyme Therapeutics’s price target?
            The average price target for Halozyme Therapeutics is 93.75. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $115.00 ,the lowest forecast is $57.00. The average price target represents 14.43% Increase from the current price of $81.93.
              What do analysts say about Halozyme Therapeutics?
              Halozyme Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of HALO?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.